PMA 101R

Drug Profile

PMA 101R

Alternative Names: PMA-101R

Latest Information Update: 18 Jul 2016

Price : $50

At a glance

  • Originator Pharmedartis
  • Class Anti-inflammatories; Antineoplastics; Skin disorder therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Atopic dermatitis; Inflammation; Psoriasis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 18 Jul 2016 PMA 101R is still in preclinical development for Acute myeloid leukaemia, Solid tumours, Inflammation, Rheumatoid arthritis, Atopic dermatitis and Psoriasis in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top